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Abstract
A literature survey was conducted on herbs, their preparations and ingredients with reported liver
protection activities, in which a total of 274 different species and hundreds of active ingredients
have been examined. These ingredients can be roughly classified into two categories according to
their activities: (1) the main ingredients, such as silybin, osthole, coumarin, glycyrrhizin,
saikosaponin A, schisandrin A, flavonoids; and (2) supporting substances, such as sugars, amino
acids, resins, tannins and volatile oil. Among them, some active ingredients have hepatoprotective
activities (e.g. anti-inflammatory, anticancer, antioxidant, immunomodulating and liver cirrhosis-
regulating effects). Calculation of physicochemical parameters indicates that the main ingredients
with negative and positive Elumo values possibly display their hepatoprotective effects through
different mechanisms, such as antioxidative, anti-inflammatory and immunomodulating effects. As
the combination of herbs may achieve some treatment effects synergistically and/or additively, it is
common in Chinese medicine to use mixtures of various medicinal herbs with pharmacologically
active compounds to have synergistic and/or additive effects, or to reduce harmful effects of some
pharmacologically active compounds. In particular, the active compounds with Clog P around 2 are
suitable for passive transport across membranes and accessible to the target sites. Thus, Elumo and
Clog P values are good indicators among the calculated parameters.
Seven different physicochemical parameters (MW, Clog P, CMR, μ, Ehomo, Elumo and Hf) and four
major biological activities (antioxidant, anti-inflammatory, antiviral/antitumor and
immunomodulating) are discussed in this review. It is hoped that the discussion may provide some
leads in the development of new hepatoprotective drugs.
Background
It is well recognized that liver is one of the most important
organs in the biotransformation of food, drugs, endog-
enous and exogenous substances. Profuse supply of blood
and the presence of many redox systems (e.g. cytochromes
and various enzymes) enable liver to convert these sub-
stances into different kinds of inactive, active or even toxic
metabolites. The burden of metabolism and exposure to
dangerous chemicals make liver vulnerable to a variety of
disorders, such as acute or chronic inflammation, toxin-/
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drug-induced hepatitis, cirrhosis and hepatitis after viral
infection.
For centuries, many herbs have been used as natural rem-
edies for the prevention and/or treatment of liver diseases.
Various herbs and herbal products are believed to have
liver protective functions and widely used in clinical prac-
tice in the West as well as East. In the First Edition of PDR
for Herbal Medicine [1], for example, a total of 49 herbal
products were listed under the preparations for clinical
use in liver and gall bladder complaints and 32 products
for liver disorders. Some complex Chinese herbal formu-
lae, such as Pro-liver Pill (Yanggan Wan)[2], Liver Care
(Himalaya Drug Co, Bangalore, India), Liv-52 [3], Jianpi
Wenshen Pill (Jianpi Wenshen Wan) [4], Binggan capsules
(Binggan Jiaonang) [5], Binggan Tang [6],  Yizhu  decoc-
tion(Yizhu Koufuye) [7], Yiergan Tang [8] and Xiaochaihu
Tang (Sho-saiko-to or SST,) [9], have been reported to have
significant therapeutic effects on liver protection or treat-
ment of liver diseases. It is yet to be established as to
which of the herbs and their active ingredients in these
formulae contribute most to the activities of liver protec-
tion and treatment.
Both manual and electronic search of literature and/or
biological information in herbal medicine was carried out
in order for us to examine which structural and physico-
chemical factors probably affect hepatoprotection. Based
on two reference books, namely Zhongcaoyao Xiandai Yan-
jiu [10-12] and The Chemical Constituents of Oriental Herbal
Drugs (Vol 1 & 2) [62,63], electronic literature search was
performed with "ovid"(an online resource with access to
multiple databases such as Medline, Biosis, Embase, Cur-
rent Contents, as well as journals and books), by the key
words of "herbal medicine with hepatoprotective activity"
and was mainly focused on the literature from 1995 to
2005. In this review, most of the reported ingredients of
the heptoprotective herbs are summarized and listed
under family, genus and species names of the herbs (Addi-
tional file 1) and seven physicochemical parameters of the
hepatoprotective compounds, namely molecular weight
(MW), calculated octanol/water partition coefficient
(Clog P), molar refraction (CMR), dipole moment (μ),
energy of the highest occupied molecular orbital (Ehomo),
energy of the lowest unoccupied molecular orbital (Elumo)
and heat of formation (Hf), have been calculated and
reported (Additional file 3). Chemical structures of some
of the representative compounds together with their
respective calculated physicochemical parameters are also
provided (Additional file 2).
Biological activities of extracts and ingredients 
of medicinal herbs
According to the results from our literature survey, nearly
300 species of plants belonging to 92 different families
have been reported to have liver protection or therapeutic
effects on hepatic disorders (Additional file 1). Families of
Compositae, Labiatae and Leguminosae cover the largest
numbers of species.
These plant species usually contain phytochemicals such
as phenols, organic acids, flavonoid glycosides, tannins,
resins, amino acids, sugars, alkaloids, saponins and vola-
tile oil as well as their own unique constituents. It is not
clear whether one, several or all of these components are
active ingredients for liver protection. It is likely that some
specific ingredients of each herb play a vital role in liver
protection/treatment, thereby contributing to their thera-
peutic effects. Structures of some representative liver pro-
tective compounds [10-34] and key physicochemical
parameters which may affect their pharmacokinetic and
pharmacodynamic effects are provided (Additional file
2).
Among the many hepatoprotective herbs/compounds,
milk thistle (Silybum marianum) used in the West [35], gly-
cyrrhizin, Bupleurum chinense (Saiko), Schisandra chinensis
(Wuweizi) and Phyllanthus amarus used in traditional Chi-
nese medicine have been most extensively studied and
documented [36].
Silymarin, a mixture of flavonolignans extracted from the
seeds of Silybum marianum, is most widely used as a rem-
edy for liver diseases. It is composed of four isomers: the
major active component silybin, isosilybin, silychristin
and silydianin (Figure 1). Moreover, other seed constitu-
ents of Silybum marianum such as betaine, other flavono-
lignans and essential fatty acids from the same plant have
been shown to have anti-inflammatory properties [37].
The beneficial effects of silymarin are most often observed
in patients with cirrhosis as a result of alcohol abuse [38].
But it does not reduce mortality; nor does it improve liver
histology or biochemical markers of liver function among
patients with chronic liver diseases [35]. It was reported
that treatment with Silybum marianum and its constituents
appears to be safe with no signs of adverse effects [15].
Glycyrrhizin (GL), isolated from the water-soluble extract
of Glycyrrhiza uralensis, has been orally or intravenously
administered for the treatment of chronic viral hepatitis
[34]. It was discovered that GL is metabolized into 18β-
glycyrrhetinic acid (GA) and 18β-glycyrrhetinic acid-3-O-
β-D-glucuronide (GAMA) by β-D-glucuronidase in the
liver and intestines [39,40] (Figure 2).
Structure-bioactivity relationship studies indicate that GA
is the most active ingredient against platelet aggregation,
tumor cell lines, rotavirus infection and growth of Helico-
bacter pylori, followed by GAMA and GL [41]. Thus, GA is
a better hepatoprotective drug than GAMA or GL. It hasChinese Medicine 2007, 2:5 http://www.cmjournal.org/content/2/1/5
Page 3 of 8
(page number not for citation purposes)
Structures of the four isomers in silymarin Figure 1
Structures of the four isomers in silymarin.
O
O
O
OH O
OH
O H
CH2OH
OH
OMe
Isosilybin        
O
O
O
OH
OH O
OH
O H
OH
OMe
Silybin  
    
O
OH O
OH
O H
OH
O
CH2OH
OH
OMe
Silychristin
OH
OMe
O
OH O
OH
O H O
O
OH
Silydianin      
Metabolism of glycyrrhizin catalyzed by β-D-glucuronidase in human liver and intestines Figure 2
Metabolism of glycyrrhizin catalyzed by β-D-glucuronidase in human liver and intestines.
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been suggested that GL (a natural prodrug and sweet prin-
cipal of Glycyrrhiza) and its hydrolytic metabolites
(GAMA, GA) bind to hepatocytes to modify the expres-
sion of HBV (hepatitis B virus)-related antigens and sup-
press sialylation of hepatitis B virus surface antigen
(HbsAg) [34,42]. Clinical studies showed that GL has
comparable antiviral effects to those of interferon and that
it is effective in reducing complications of chronic hepati-
tis C without apparent side-effects [43,44].
Schisandra chinensis (Wuweizi), traditionally used as a
tonic, is now widely used for the treatment of chemical/
viral hepatitis. Biological studies indicate that seed extract
of Schisandra chinensis can enhance hepatic GSH (glutath-
ione) antioxidant/detoxification system and facilitate
both processes in the liver. It may be a promising agent for
improving phase I oxidative metabolism in liver damaged
by CCl4[45]. Chemical investigations on the extract have
revealed the presence of lignans with a dibenzocycloocta-
diene skeleton such as schisandrin, gomisin A, deoxy-
schisandrin (schisandrin A), γ-schisandrin and wuweizisu
C [46] (Figure 3). These components are believed to be
active in hepatoprotective, anti-inflammatory, anticancer,
anti-HIV and immunomodulating effects [47-50].
Structure-activity relationship (SAR) analyses suggest that
the presence of methylenedioxy/a hydroxyl group in the
dibenzocyclooctadiene skeleton is an important structural
feature for hepato- and neuro-protective activities [51,52].
Osthole, a coumarin derivative contained in many medic-
inal plants especially in Boenninghausenia albiflora, was
reported to protect against liver injury, and these effects
are related to the presence of 7-methoxy and 3-methyl-2-
butenyl groups in the structure [53,54]. Due to its low tox-
icity, osthole appears to be suitable for the treatment of
chronic hepatitis and can be used as a lead compound for
further development of orally ingested hepatoprotective
drugs.
Apart from single herbal medicine, 'Kampo medicine'
which utilizes combinations of raw herbs, was widely
used in Japan, among which SST is the most well-known.
It is a spray-/freeze-dried extract from seven medicinal
herbs (Bupleurum falcatum, Glycyrrhiza glabra, Panax gin-
seng, Pinellia ternate, Scutellaria baicalensis, Zizyphus jujube
and Zingiber officinale). Many clinical and experimental
studies demonstrated that SST has a variety of therapeutic
effects ranging from anti-inflammatory, antioxidant
immunomodulating to hepatoprotective, especially on
chronic hepatitis. HPLC (high performance liquid chro-
matography) analysis of pharmacologically active ingredi-
ents in SST indicated that the major fractions of SST
contain compounds of flavonoid-like structures (e.g. bai-
calin, baicalein, liquiritin) and triterpene saponins (GL,
saikosaponins b1 & b2, ginsenosides Rg1 and Rb1) [55]
(Figure 4). Comparative experiments showed that the
liver concentrations of the active constituents of SST
extract in the liver-injured rats increased significantly after
the animals received SST extract, as compared with the
groups receiving the respective purified constituents.
Thus, administration of SST extract was more useful than
that of its active ingredients individually [56].
In summary, the ingredients as stated above possess
hepatoprotective activities, ranging from antiviral, anti-
inflammatory, anticancer, antioxidant to immunomodu-
lating and liver cirrhosis regulating effects. Why do the
active constituents with different structural features have
common biological activities? There may be some innate
factors affecting liver protective activities.
SAR analysis of some hepatoprotective 
ingredients
A total of 82 representative compounds belonging to nine
major groups (i.e. oleanolic acids, hederagenins, polysac-
charides, rehmanniosides, xanthine derivatives, alkenes &
alkanes, camelliagenin & theasapogenol, campenosides &
flavonoids, and aromatic compounds) have been
reported to have hepatoprotective effects (Additional file
3). Seven different physicochemical parameters, namely
the Clog P, CMR, μ, Ehomo, Elumo, Hf and MW, have been
selected as molecular indicators:
(1) Elumo values can be divided into three subsets ranging
from -1.12 ~ -0.10, and 0.03 ~ 1.07, to 1.10 ~ 2.12 (Addi-
tional files 2 and 3). As Elumo values reflect electron affinity
of the respective compounds [57], these positive and neg-
ative ranges may indicate different mechanisms of actions
in hepatoprotection. For example, the Elumo values of Sily-
bum marianum, osthole, coumarin, as well as flavonoids
and their glucosides, ranging from -1.03 to -0.83, suggest
that their hepatoprotective activities may be achieved via
their antioxidative properties, while glycyrrhizin, Schisan-
dra chinensis and Bupleurum chinense, with their Elumo val-
ues ranging from 0.03 to 1.07, possibly exert their liver
protection through other mechanisms (e.g. anti-inflam-
matory and/or immunomodulating).
(2) Clog P value, a measure of the hydrophobicity of the
compound, may contribute to hydrophobic interactions
when the compound binds to the receptor. Different
series of compounds vary considerably in their ClogP val-
ues (Additional file 3). Polysaccharides, rehmanniosides,
rutin, caffeine and theophylline have negative Clog P val-
ues ranging from -0.06 to -7.82. Conversely correlated
with the number of sugar moieties attached to the corre-
sponding structures, the Clog P values of camelliagenins,
theasapogenols, oleanolic acids and hederagenins are
mostly above 4. The presence of sugar units decreases the
partition coefficient of the core structures in the directionChinese Medicine 2007, 2:5 http://www.cmjournal.org/content/2/1/5
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of the values getting closer to the ideal log P0 of 2 and
facilitates transmembrane absorption in human body
before the compounds' binding to the receptors [58-60].
Other series of compounds have Clog P between 0.7 and
4.0. The more active compounds in hepatoprotection
have more favorable Clog P values around 2, such as sily-
bin (1.94), glycyrrhizin (1.89) and coumarin derivatives
(1.4~3.7), which are suited for passive transport across
membranes and make it easier for the compounds to
access the target sites (Additional file 2).
(3) An indicator of the potential of dipolar interactions
among molecules, μ may have some effects on transmem-
brane absorption as well as interactions with receptors
once the molecules are administered and transported via
body fluid. The dipole moment values can be roughly
divided into three subgroups: high (9.26 – 6.12), medium
(5.98 – 1.62) and low (1.45 – 0.24) (Additional file 3). It
was anticipated that compound with high or low value of
dipole moment would not possess ideal biological activ-
ity because it was difficult to cross multiple biological
membranes to reach active sites. Some prodrugs with high
values of dipole moment (glycyrrhizin: 7.01) may still
display some biological activities after metabolic removal
of the polar group (18 β-Glycyrrhetinic acid: 5.83). Only
the compounds with medium dipole moment values pos-
sibly have satisfactory hepatoprotective activities (silybin:
1.92; osthole: 3.77). Finally, MW and Hf values of these
compounds may have some effects on their biological
activities in their own ways (Additional file 3).
Structures of the dibenzocyclooctadiene compounds and osthole Figure 3
Structures of the dibenzocyclooctadiene compounds and osthole.
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Although biological effects of these ingredients have not
been fully elucidated by these data, the antioxidant activ-
ities are indicated in their Elumo values. It is speculated that
the compounds with negative Elumo values may act as free
radical scavengers by having one electron from the highest
occupied molecule orbital (HOMO) changed to the low-
est unoccupied molecule orbital (LUMO), thereby elimi-
nating the damaging effects of free radicals. The damaging
effects of oxidation on the biological system via radical
mechanism and the hepatoprotective effects by antioxi-
dants and/or free radical scavengers are illustrated in Fig-
ure 5[61].
Conclusion
Herbal medicine has been used in China for more than
two thousand years and is now being gradually accepted
worldwide, particularly in Asia, Europe and the North
America. Differences, however, do exist between the East
and West in the areas such as philosophical view point,
concept of diseases and treatment approaches. In the
West, people tend to use a single herb in therapies and try
to identify active ingredients and therapeutic mecha-
nisms, whereas in Chinese medicine it is common to use
mixtures of various medicinal herbs which contain a
range of pharmacologically active compounds working
additively/synergistically to treat patients or to reduce
harmful effects of some chemical compounds. It is our
hope that the integration of Chinese and Western medi-
cine will not only identify different ingredients with simi-
lar bioactivities or similar ingredients with different
bioactivities, but also provide us with methods for quality
control in herbal medicine and clues to elucidate action
mechanisms of active ingredients.
This review is a summary of 274 species (in 216 genera
among 92 families) of herbs that have been reported to
have positive effects on liver protection and treatment, as
well as hundreds of active ingredients. These ingredients
can be roughly classified into two categories: (1) the main
ingredients, such as silybin, osthole, coumarin, glycyr-
rhizin, saikosaponin A, schisandrin A, flavonoids, and (2)
the supporting substances, such as sugars, amino acids,
resins, tannins and volatile oil. Calculations of molecular
parameters suggest that negative and positive Elumo values
in the main ingredients represent two different hepato-
protective mechanisms. The main ingredients with nega-
tive Elumo values may display their hepatoprotective effects
through an antioxidative mechanism, whereas other
ingredients with positive Elumo values may act via an anti-
inflammatory and/or immunomodulating mechanism.
Moreover, the Clog P values of many pharmacologically
active compounds are around two and other ingredients
with higher or lower Clog P values usually go through
metabolic processes in which some hydrophilic groups
are added or removed so that their Clog P values are
around two. Elumo and Clog P values, therefore, should be
useful in the future development of hepatoprotective
drugs.
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